IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference

Rhea-AI Summary

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm specializing in engineered IgM antibodies, announced that CEO Fred Schwarzer will present at the Jefferies 2020 Healthcare Conference. The presentation is scheduled for Thursday, June 4, at 10:00 a.m. ET, and will be conducted virtually. Interested participants can access a live webcast through the company’s website, with a replay available for 90 days post-event. IGM Biosciences focuses on advancing IgM antibody technologies, addressing existing manufacturing challenges since its inception in 2010.

News Market Reaction – IGMS

+2.67%

+2.67% Session move

In the trading session that priced this news, IGMS gained 2.67%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOUNTAIN VIEW, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Thursday, June 4 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

When will IGM Biosciences present at the Jefferies 2020 Healthcare Conference?

IGM Biosciences will present on Thursday, June 4, 2020, at 10:00 a.m. ET.

Where can I watch the IGM Biosciences presentation at the Jefferies Conference?

The presentation will be available via a live webcast on IGM Biosciences' 'Events and Presentations' page.

What is the main focus of IGM Biosciences?

IGM Biosciences is focused on developing engineered IgM antibodies for various clinical applications.

How long will the webcast of IGM Biosciences' presentation be available?

A replay of the webcast will be archived for 90 days following the presentation.

What date was the IGM Biosciences press release issued?

The press release was issued on May 28, 2020.